#EHA2021 and ASCO 2021 showcased compelling evidence on ‘off-the-shelf’ therapies – allogenic CAR-Ts, dual targeting CAR-Ts, or NK cell therapy. Learn more about SmartAnalyst’s perspective on the evolving data
vs current SoCs.

Click here to read more: Highlights from EHA 2021